“There are several stocks which are not really in your comfort zone and hence we need to pick up stocks on a bottom-up basis and need to cherry-pick ideas wherein the risk-reward is favourable. Otherwise, it is a tough market as far as stock selection is concerned,” says Pawan Parakh, Geojit Financial Services. What a … Read more
“For this September series, we expect the range for September series for Nifty is 24,800 on the downside and on the higher side 25,600, this is going to be the possible range for Nifty. For Bank Nifty, the immediate supply zone which is placed is around 51,500 which is very important level to cross on … Read more
Amit Khurana, Head of Equities, Dolat Capital, says a serious outperformance by India from here in the near term, looks a little bit of a challenge. But India remains the best emerging market to play over the next few years. But near term, some normalisation is required to get to healthy market levels and price … Read more
Most technical charts and options data hint at a bullish setup. According to technical analysts, Nifty is expected to continueits upward trajectory towards 23,560, followed by 23,890, with immediate support at 23,000. Analysts suggest Tata Motors,UltraTech Cement, Sun Pharma, McDowell, UBL, ITC, Marico, HUL, Tata Consumer, and Lupin for short-term trading. SHILPA ROUT, AVP – … Read more
The India Meteorological Department (IMD) announced its stage-2 long-range forecast for southwest monsoon 2024. It has retained its outlook of an above-normal monsoon this year. It expects rainfall in the upcoming monsoon to be at an eight-year high of 106% (with an error margin of +/-5%) of the long-period average of 870mm for the four-month … Read more
“The fact bond yields went down when you had that big dividend payout, I think there was a bit of an outperformance. So, I think you could look for some more outperformance at least over the next 6 to 12 months,” says Hemang Jani, Independent Market Expert.But the interesting bit is despite the fact that … Read more
“In North America, Revlimid is the key contributor and again, speciality drugs for Zydus Lifesciences that will keep on increasing EBITDA margins towards 29-30% and also in the valuation-wise Zydus Life is not trading at much higher valuations like Sun, therefore we feel that Zydus Life is also a second stock which can see good … Read more
“There might be some psychological or emotional reaction in a shorter term, saying government would not be able to carry out this reform, that reform, but I do not think structurally speaking anything would change,” says Vikas Khemani, Carnelian Asset Management.The main plank of this government’s politics or one would say this entire canvassing has … Read more
Sandip Sabharwal, asksandipsabharwal.com, says “the markets have corrected and people are correlating it to what might happen in the election. I do not think that is the right way to do it. I think markets fall under their own weight when they become overweight. So, the Indian market became overweight and is correcting a bit. … Read more
“You can see from foreign flows perspective that that rebound in China is detracting from some of the investment in India. I do not think it changes the longer-term trends, but we are in one of those holding patterns similar to the fourth quarter of 2023,” says Laurence Balanco, CLSA.What is the take on India … Read more
